Association between antipsychotic drugs and diabetes
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The link between atypical antipsychotic drugs and the development of diabetes has been hotly debated in the literature. In this review, we attempt to classify the various types of data published and presented in a hierarchical basis. Case reports and retrospective pharmacoepidemiological studies suggest that both conventional and atypical antipsychotic medications are associated with an increased risk of glucose abnormalities or diabetes. Prospective data examining the relationship between atypical antipsychotic drugs and diabetes began to emerge in 2003 and are much less conclusive. Estimates of the attributable risk associated with atypical antipsychotic drugs are low. The few studies that have included a placebo group suggest that we cannot necessarily blame antipsychotic medication when diabetes develops in an individual with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R. (2002) · BMJ · doi:10.1136/bmj.325.7358.243 · Cited by 421
Assessing the potential for α-glucosidase inhibitors in prediabetic states
Holman, R. R. (1998) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(98)00038-2 · Cited by 197
Antipsychotics and diabetes: review of non-prospective data
Haddad, P. M. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.47.s80 · Cited by 71
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
“Evidence suggests that the prevalence of DM in people with schizophrenia as well as in people with bipolar disorder and schizoaffective disorder is 2-3 fold higher compared with the general population (103,209-216).”
BackgroundSerious mental illness and physical health problems: A discussion paper
Robson, D., & Gray, R. (2007) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2006.07.013 · Cited by 411
“Controversy exists about the prevalence and aetiology of diabetes in people with SMI (Holt and Peveler, 2005).”
BackgroundDiabetes mellitus and severe mental illness: mechanisms and clinical implications
Holt, R. I. G., & Mitchell, A. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.203 · Cited by 179
Self-citationVerhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53
“SGAPs promote lipogenesis and enhance antilipolytic effects of insulin, thereby favoring lipid accumulation and adipocyte enlargement and inducing insulin resistance [40, 53, 54].”
BackgroundObstructive sleep apnoea and schizophrenia — A research agenda
Kalucy, M. J., Grunstein, R., Lambert, T., & Glozier, N. (2013) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2012.10.003 · Cited by 55
Metadata
- Authors
- Holt, R. I. G., & Peveler, R. C.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2005-04-25
- Volume
- 8
- Issue
- 2
- Pages
- 125-135
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1982501208
- Cited by
- 73
- References
- 4
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association between antipsychotic drugs and diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2005.00495.x
- The paper
- Holt, R. I. G., & Peveler, R. C. (2006). Association between antipsychotic drugs and diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2005.00495.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.